Medicure (MPH) Q3 2025 earnings summary

Executive summary

• Net revenue for Q3 2025 was CAD 8.2 million, up from CAD 5.2 million in Q3 2024, driven by pharmacy acquisitions and Zypitamag growth.

• Reported a net loss of CAD 1.4 million (CAD 0.13 per share) versus net income of CAD 680,000 (CAD 0.07 per share) in Q3 2024, mainly due to lower Aggrastat revenue and higher costs.

• Adjusted EBITDA was negative CAD 597,000 in Q3 2025, compared to negative CAD 467,000 in Q3 2024.

• Focus areas include Aggrastat, Zypitamag, Marley Drug, MC-1 development, and new chemical entities.

Financial highlights

• Zypitamag sales rose 21% year-over-year to CAD 1.7 million; Marley Drug revenue increased 22% to CAD 3.3 million.

• Aggrastat revenue declined to CAD 1 million from CAD 1.9 million due to generic competition and pricing pressures.

• Gateway Medical Pharmacy and West Olympia Pharmacy, acquired in 2025, contributed a combined CAD 3.1 million in Q3 revenue.

• Gross profit for Q3 2025 was CAD 2.8 million, unchanged from Q3 2024.

• Cash balance was CAD 4.1 million as of September 30, 2025, down from CAD 7.2 million at year-end 2024.

Outlook and guidance

• Short-term goals: grow Zypitamag and Marley Drug, maintain Aggrastat sales, and advance MC-1 for FDA approval.

• Long-term focus on developing new intellectual property for large market diseases.